Tenders Are Invited For Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accord ... in Germany

Work Detail

Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Combination Of Lamivudine, Tenofovir Disoproxil And Doravirine (Atc Code: J05ar24).. The Aok Lower Saxony. The Health Insurance Company Intends To Conclude Non-Exclusive Drug Discount Contracts For The Active Ingredient Combination Of Lamivudine, Tenofovir Disoproxil And Doravirine (Atc Code: J05ar24) With As Many Market Participants As Possible (Pharmaceutical Companies Or Communities Of Pharmaceutical Companies) In The So-Called “Openhouse Model” Until Exclusive Contracts Come Into Force After A Public Tender In Accordance With The Regulations Of Part 4 Of The Gwb. Aok Niedersachsen Will Not Make A Selection Decision And Will Make An Identical Contract Offer To Every Interested Pharmaceutical Company. In The Openhouse Model, Uniform Conditions Apply To All Participants. Contract Contents, Conditions And Access Procedures Are Uniform - Individual Negotiations Are Generally Not Carried Out. The Contract Terms Are A Maximum Of Twenty-Four Months; The Earliest Contract Start Date Is March 1, 2026. All Contracts End On February 29, 2028 At The Latest, Regardless Of The Date Of Conclusion Of The Respective Contract. Joining Or Concluding A Contract Can Take Place On The First Of Each Month Within The Twenty-Four Month Period. There Is A Right Of Termination Six Weeks To The End Of The Month. Aok Niedersachsen Reserves The Right To Replace The Non-Exclusive Openhouse Discount Agreements With Exclusive Discount Agreements During The Contract Term. When Advertised, Exclusive Discount Contracts Come Into Force, The Openhouse Contracts Will Be Terminated In Accordance With The Contractual Regulations, I.E. H. The Open House Contracts End Automatically. According To Aok Niedersachsens Experience, Exclusive Discount Agreements Usually Come Into Force Six To Eight Months After The Publication Of The Corresponding Tender Notice In The Supplement To The Official Journal Of The European Union. The Future Contractual Partners In The Openhouse Model Are Requested To Regularly Consult The Supplement To The Official Journal Of The European Union Regarding These Tender Notices. Interested Pharmaceutical Companies Can Request The Contract Documents And The Contract Conditions At The Contact Address Mentioned Under I.1). Contracts For The Active Ingredient Combination Of Lamivudine, Tenofovir Disoproxil And Doravirine (Atc Code: J05ar24) Will Be Concluded For The First Time With Effect From March 1, 2026. Interested Parties Who Would Like To Become Contractual Partners On This Date Must Submit The Contract Documents To Be Submitted By January 26, 2026 To The Address Specified In The Contract Documents. It Depends On Access To Aok Niedersachsen. Later Contracts Are Possible During The Twenty-Four-Month Maximum Term On The First Of Each Month. From An Organizational Point Of View, The Aok Generally Needs A Lead Time Of 35 Calendar Days To Carry Out The Necessary Work, E.G. B. To Be Able To Ensure Contract Reporting In The Lauertaxe®. The Exact Deadlines For Receipt Will Be Provided

Contact Information